01—Abstract
Summary
Summary of the 8-K filed April 25, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 net sales of $695.4 milliona, down 3.0%, with organic net sales also declining 3.0%.
Reported-diluted EPS was $1.55b, down 16.2%, and adjusted-diluted EPS was $1.56, down 21.2%. Net income was $115.3 million versus $140.0 million a year earlier. The Proprietary Products segment net sales declined 4.0% to $559.5 million, while the Contract-Manufactured Products segment rose 1.8% to $135.9 million.
Cash flow weakened in the quarter. Operating cash flow was $118.2 millionc, a decrease of 14.4%, and capital expenditures were $90.6 million, leaving free cash flow of $27.6 million, down 50.7%. Cash and cash equivalents fell to $601.8 million at March 31, 2024 from $853.9 million at December 31, 2023.
During the quarter the company repurchased 729,679 shares for $267.0 milliond at an average price of $365.87. Full-year 2024 guidance for net sales of $3.000 billion to $3.025 billion was reaffirmed, with organic growth expected at approximately 2% to 3%. Adjusted-diluted EPS guidance was raised to $7.63 to $7.88 from $7.50 to $7.75, including a $0.15 benefit from first-quarter stock-based compensation tax benefits.
Management attributed near-term headwinds to customers managing the timing of inventory decisions and expects stronger organic sales growth in the second half of the year. The Board also approved a third-quarter 2024 dividend of $0.20 per share, payable August 7, 2024.
02—Key points
Key Highlights
- Net sales of $695.4 million declined 3.0%, with organic net sales also down 3.0%.
- Reported-diluted EPS of $1.55 declined 16.2%; adjusted-diluted EPS of $1.56 declined 21.2%.
- Proprietary Products sales fell 4.0% to $559.5 million; Contract-Manufactured Products sales rose 1.8% to $135.9 million.
- Full-year 2024 net sales guidance of $3.000 billion to $3.025 billion was reaffirmed.
- Adjusted-diluted EPS guidance raised to $7.63 to $7.88 from $7.50 to $7.75.
- Operating cash flow of $118.2 million fell 14.4%, and free cash flow of $27.6 million fell 50.7%.
- Repurchased 729,679 shares for $267.0 million during the quarter; declared a $0.20 per share third-quarter dividend.
03—Questions
Frequently Asked Questions
Did West Pharmaceutical change its full-year 2024 outlook?
Net sales guidance was reaffirmed at $3.000 billion to $3.025 billion, with organic growth expected at approximately 2% to 3%. Adjusted-diluted EPS guidance was raised to $7.63 to $7.88 from $7.50 to $7.75. The increase includes a $0.15 benefit from first-quarter stock-based compensation tax benefits.
What drove the decline in first-quarter results?
The company cited the timing of inventory decisions by some customers. Declines in the Proprietary Products segment, including FluroTec and Westar components and standard components, were only partly offset by growth in NovaPure, self-injection device platforms and Daikyo Crystal Zenith components. Gross profit margin fell to 33.1% from 37.9%.
How did cash flow and the balance sheet change?
Operating cash flow was $118.2 million and capital expenditures were $90.6 million, leaving free cash flow of $27.6 million. Cash and cash equivalents decreased to $601.8 million from $853.9 million at year-end 2023, and debt was $206.2 million at March 31, 2024.
What is the dividend and buyback activity?
The Board approved a third-quarter 2024 dividend of $0.20 per share, payable August 7, 2024, to shareholders of record as of July 31, 2024. During the quarter, the company repurchased 729,679 shares for $267.0 million at an average price of $365.87.
What does management expect for the rest of 2024?
Management said recent order trends reinforce its prior outlook for stronger organic sales growth in the second half of the year. Full-year 2024 capital spending is unchanged at $350 million, and the company continues investing in new manufacturing capacity in both segments.
04—Continue